FDA nod on malaria drug pressures La Jolla Pharma

La Jolla Pharmaceutical (NASDAQ:LJPC) is down 20% premarket on modestly higher volume on the heels of the FDA’s approval of Amivas LLC’s IV artesunate for severe malaria, an Orphan Drug-tagged indication.

The thumbs up bodes ill for La Jolla’s LJPC-0118, also an IV artesunate, since the Amivas product will have a seven-year period of market exclusivity in the U.S. for the indication. Severe malaria is not a problem here, but certain other countries rely on the FDA nod to approve drugs locally.

https://seekingalpha.com/news/3577878-fda-nod-on-malaria-drug-pressures-la-jolla-pharma